PVCT News and Press, Provectus Biopharmaceuticals Inc From 09/21/20

Near-resolution of tumor burden, including extensive visceral hepatic disease Expanded data set of trial subject provided KNOXVILLE, TN, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today highlighted the clinical outcome of a Stage IV M1c patient (Subject 0112) in ...

OTC company Provectus ( OTC:PVCT +3.0% ) has announced preliminary data from its Phase 1b/2 study of PV-10 in combination with Merck's KEYTRUDA for the treatment of advanced cutaneous melanoma in patients who did not respond to single- and dual-agent checkpoint blockade (CB) treatment....

36% ORR and 64% DCR (RECIST 1.1) PV-10-induced, tumor-specific restoration of T cell function Data compare favorably to approved and investigational therapies for patient population KNOXVILLE, TN, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that prelimin...

62% 2-year OS; median OS not reached Stable, non-overlapping safety profile Clinical synergy between PV-10 and immune checkpoint blockade Data compare favorably to approved therapies for patient population KNOXVILLE, TN, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) toda...

KNOXVILLE, TN, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with Michio Kurosu, PhD, Professor, Department of Pharmaceutical Sciences at the College of Pharmacy of the University of Tennessee Healt...

Provectus ( OTC:PVCT -1.9% ) has expanded its sponsored research collaboration with the University of Calgary, under which the research team will now investigate oral dosing of Provectus's rose bengal disodium (RBD) in  in vivo  murine models for r...

University of Calgary researchers have successfully demonstrated initial, in vivo proof-of-concept, oral rose bengal disodium treatment for blood cancer Researchers will now investigate oral treatment for high-risk adult solid tumor cancers KNOXVILLE, TN, Aug. 13, 2020 (GLOBE NEWSWIR...

KNOXVILLE, TN, July 22, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce that data from an ongoing clinical trial of investigational autolytic cancer immunotherapy PV-10 (rose bengal disodium) in combination with immune checkpoint blockade for the treatment of a...

KNOXVILLE, TN, July 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce the addition of Webster Bailey to the Company's Board of Directors (the “Board”), effective as of July 20, 2020. Mr. Bailey is a member of the board of directors of the Clover...

PV-10 treatment leads to STING dimerization Researchers identify potential association of heat shock proteins with STING in PV-10-treated models KNOXVILLE, TN, June 22, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce that data from ongoing preclinical stud...